Ferrous Iron Is a Significant Component of Bioavailable Iron in Cystic Fibrosis Airways
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
UNLABELLED: ABSTRACT Chronic, biofilm-like infections by the opportunistic pathogen Pseudomonas aeruginosa are a major cause of mortality in cystic fibrosis (CF) patients. While much is known about P. aeruginosa from laboratory studies, far less is understood about what it experiences in vivo. Iron is an important environmental parameter thought to play a central role in the development and maintenance of P. aeruginosa infections, for both anabolic and signaling purposes. Previous studies have focused on ferric iron [Fe(III)] as a target for antimicrobial therapies; however, here we show that ferrous iron [Fe(II)] is abundant in the CF lung (-39 µM on average for severely sick patients) and significantly correlates with disease severity (ρ = -0.56, P = 0.004), whereas ferric iron does not (ρ = -0.28, P = 0.179). Expression of the P. aeruginosa genes bqsRS, whose transcription is upregulated in response to Fe(II), was high in the majority of patients tested, suggesting that increased Fe(II) is bioavailable to the infectious bacterial population. Because limiting Fe(III) acquisition inhibits biofilm formation by P. aeruginosa in various oxic in vitro systems, we also tested whether interfering with Fe(II) acquisition would improve biofilm control under anoxic conditions; concurrent sequestration of both iron oxidation states resulted in a 58% reduction in biofilm accumulation and 28% increase in biofilm dissolution, a significant improvement over Fe(III) chelation treatment alone. This study demonstrates that the chemistry of infected host environments coevolves with the microbial community as infections progress, which should be considered in the design of effective treatment strategies at different stages of disease. IMPORTANCE: Iron is an important environmental parameter that helps pathogens thrive in sites of infection, including those of cystic fibrosis (CF) patients. Ferric iron chelation therapy has been proposed as a novel therapeutic strategy for CF lung infections, yet until now, the iron oxidation state has not been measured in the host. In studying mucus from the infected lungs of multiple CF patients from Europe and the United States, we found that ferric and ferrous iron change in concentration and relative proportion as infections progress; over time, ferrous iron comes to dominate the iron pool. This information is relevant to the design of novel CF therapeutics and, more broadly, to developing accurate models of chronic CF infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIG 1 Direct detection of iron abundance and oxidation state within CF sputum. Total iron [Fe(III) plus Fe(II)] (A), Fe(II) (B), and Fe(II) % (D) all increase as pulmonary function (FEV1%) declines. There is no significant increase in Fe(III) (C). Each point represents the average of measurements on multiple sputum samples from a single CF patient.](https://figures.cochat.ai/paper-figures/1c514780f0884b5bb5002e77d9f11db2/ferrous-iron-is-a-significant-component-of-bioavailable-iron-in-cystic-fibrosis-figure-1.jpg)


![FIG 4 (A and B) Biofilm growth prevention under aerobic conditions [~98% Fe(III)] (A) and anaerobic conditions [~10 µM Fe(II) and 10 µM Fe(III)] (B) by conalbumin [a Fe(III) chelator] and ferrozine [a Fe(II) chelator]. (C and D) Biofilm dissolution under aerobic (C) and anaerobic (D) conditions by conalbumin and ferrozine. In all cases, chelator effects are mitigated by the addition of Fe in excess of the chelation capacity [80 µM Fe(III) under oxic conditions; Fe(II) under anoxia]. Asterisks represent significance versus untreated controls. Error bars represent standard errors of the means (n = 12).](https://figures.cochat.ai/paper-figures/f1d66c6634344f90919b5eb2709f220a/ferrous-iron-is-a-significant-component-of-bioavailable-iron-in-cystic-fibrosis-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, an increase in iron and iron-related proteins is found in the lungs of CF patients (Hunter et al., 2013; Quinn et al., 2014).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Hunter et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“The availability of ferrous iron correlates with disease severity on CF patient lungs (Hunter et al., 2013).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Hunter et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“In addition to nutrient limitation, decreased oxygen availability forms microenvironments where Fe(II) may be a dominant Fe source.88”
From Bacterial Responses to Iron Withholding by Calprotectin (2021) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hunter, R. C., Klepac-Ceraj, V., Lorenzi, M. M., Grotzinger, H., Martin, T. R., & Newman, D. K. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0088oc · Cited by 168
Self-citationRetractedAnalysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms
Donlan, R. M., & Costerton, J. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.167-193.2002 · Cited by 6,644 · cited 1×
“In a biofilm mode of growth, it is generally accepted that bacterial cells are inherently more resistant to antibiotics and components of the host immune system, and only once they revert to their planktonic state are they readily cleared (42).”
BackgroundGeneral considerations for lung function testing
Miller, M. R., Crapo, R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Enright, P., Grinten, C. P. M. V. D., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034505 · Cited by 2,026
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R., D’Argenio, D. A., Miller, S. I., Ramsey, B. W., Speert, D. P., Moskowitz, S. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602138103 · Cited by 1,319
Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U. E., Cekici, A., Meyer, K. C., Birrer, P., Bellon, G., Berger, J., Weiß, T., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci13870 · Cited by 1,099
A component of innate immunity prevents bacterial biofilm development
Singh, P. K., Parsek, M. R., Greenberg, E. P., & Welsh, M. J. (2002) · Nature · doi:10.1038/417552a · Cited by 1,026 · cited 1×
“Consistent with previous studies (10, 14), 100 M conalbumin prevented biofilm formation by 66% (P 0.”
ResultCystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024
Rapid Assay for Microbially Reducible Ferric Iron in Aquatic Sediments
Lovley, D. R., & Phillips, E. J. P. (1987) · Applied and Environmental Microbiology · doi:10.1128/aem.53.7.1536-1540.1987 · Cited by 954
Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U., Cekici, A., Meyer, K. C., Birrer, P., Bellon, G., Berger, J., Weiss, T., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213870 · Cited by 932
Cited by
Targeting microbial biofilms: current and prospective therapeutic strategies
Koo, H., Allan, R. N., Howlin, R. P., Stoodley, P., & Hall-Stoodley, L. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.99 · Cited by 1,800
Pseudomonas aeruginosa adapts its iron uptake strategies in function of the type of infections
Cornelis, P., & Dingemans, J. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00075 · Cited by 382
Self-citationGoss, C. H., Kaneko, Y., Khuu, L., Anderson, G. D., Ravishankar, S., Aitken, M. L., Lechtzin, N., Zhou, G., Czyz, D. M., McLean, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7520 · Cited by 369
Evidence and Role for Bacterial Mucin Degradation in Cystic Fibrosis Airway Disease
Flynn, J. M., Niccum, D., Dunitz, J. M., & Hunter, R. C. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005846 · Cited by 235
Self-citationRole of Iron Uptake Systems in Pseudomonas aeruginosa Virulence and Airway Infection
Minandri, F., Imperi, F., Frangipani, E., Bonchi, C., Visaggio, D., Facchini, M., Pasquali, P., Bragonzi, A., & Visca, P. (2016) · Infection and Immunity · doi:10.1128/iai.00098-16 · Cited by 228
Metadata
- Authors
- Hunter, R. C., Asfour, F., Dingemans, J., Osuna, B. L., Samad, T., Malfroot, A., Cornelis, P., & Newman, D. K.
- Affiliations
- California Institute of Technology (US)
- Children's Hospital Los Angeles (US)
- Vrije Universiteit Brussel (BE)
- University of Southern California (US)
- Universitair Ziekenhuis Brussel (BE)
- Department of Bioengineering Sciences, Research Group Microbiology, Flanders Interuniversity Institute of Biotechnology (VIB), Vrije Universiteit Brussel, Brussels, Belgium
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2013-08-30
- Volume
- 4
- Issue
- 4
- ISSN
- 2150-7511 (ISSN-L)
- 2161-2129
- PMC
- PMC3753050
- OpenAlex
- W2100199965
- Cited by
- 173
- References
- 53
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 11 · 2019: 22 · 2018: 16 · 2017: 15 · 2016: 17 · 2015: 17 · 2014: 14 · 2013: 3
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- mBio (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by-nc-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SCK CEN Institutional Repository (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- California Institute of Technology
- Agentschap voor Innovatie door Wetenschap en Technologie
- National Institutes of Health (1k99hl114862-01)
- National Heart, Lung, and Blood Institute (R00HL114862, 1K99HL114862, R01HL117328, K99 HL114862)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- cystic fibrosis, Pseudomonas aeruginosa, ferrous iron, iron(III), iron bioavailability, iron oxidation state, biofilm formation, iron chelation therapy, anoxia, chronic lung infection, disease severity
- MeSH terms
- Bacterial Proteins, Cystic Fibrosis, Ferrous Compounds, Humans, Iron, Lung, Pseudomonas aeruginosa, Biofilms, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ferrous Iron Is a Significant Component of Bioavailable Iron in Cystic Fibrosis Airways. https://app.cochat.ai/papers/10.1128/mbio.00557-13
- The paper
- Hunter, R. C., Asfour, F., Dingemans, J., Osuna, B. L., Samad, T., Malfroot, A., Cornelis, P., & Newman, D. K. (2013). Ferrous Iron Is a Significant Component of Bioavailable Iron in Cystic Fibrosis Airways. mBio. https://doi.org/10.1128/mbio.00557-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.